Thrombotic microangiopathy: COVID-19 or Hydroxychloroquine?

To the Editor, I read with great interest the Letter to the Editor by Jhaveri et al. reporting the first published case report of thrombotic microangiopathy in a patient with COVID-19.1 While there was a clear temporal relationship between the presentation with COVID-19 and development of thrombotic microangiopathy, I wonder whether the authors considered the possibility of a drug-induced thrombotic microangiopathy in particular hydroxychloroquine which was introduced on Day 1 of admission.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: letters to the editor Source Type: research